| Drug Name |
Nivolumab |
| Drug ID |
BADD_D01581 |
| Description |
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).[L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.[A35203] It was developed by Bristol Myers Squibb.[L12129]
Nivolumab was granted FDA approval on 22 December 2014.[L12129] |
| Indications and Usage |
Nivolumab is indicated to treat unresectable or metastatic melanoma, adjuvant treatment of melanoma, metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, and hepatocellular carcinoma.[L12129]
Nivolumab is also approved for the treatment of HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma when used in combination with a fluoropyrimidine- and platinum-containing chemotherapy regimen.[L39040] |
| Marketing Status |
approved |
| ATC Code |
L01FF01 |
| DrugBank ID |
DB09035
|
| KEGG ID |
D10316
|
| MeSH ID |
D000077594
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
67643-0021; 0003-3734; 0952-3772; 0003-3756; 0003-3774; 83157-3772; 70409-7125; 71124-0002; 68806-3772; 0003-3772 |
| UNII |
31YO63LBSN
|
| Synonyms |
Nivolumab | Opdivo | ONO-4538 | ONO 4538 | ONO4538 | MDX-1106 | MDX 1106 | MDX1106 | BMS-936558 | BMS 936558 | BMS936558 |
